• 1
    Castellani RJ, Zhu X, Lee HG, Moreira PI, Perry G, Smith MA. Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees? Expert Rev Neurother. 2007; 7: 47385.
  • 2
    Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol. 2006; 6: 40416.
  • 3
    Van Eldik LJ, Thompson WL, Ralay Ranaivo Behanna HA, Martin Watterson D. Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. Int Rev Neurobiol. 2007; 82: 27796.
  • 4
    Oprica M, Hjorth E, Spulber S, Popescu BO, Ankarcrona M, Winblad B, Schultzberg M. Studies on brain volume, Alzheimer-related proteins and cytokines in mice with chronic overexpression of IL-1 receptor antagonist. J Cell Mol Med. 2007; 11: 81025.
  • 5
    Crouch PJ, White AR, Bush AI. The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer's disease.: FEBS J. 2007; 274: 377583.
  • 6
    Tauskela JS. MitoQ - a mitochondria-targeted antioxidant. IDrugs. 2007; 10: 399412.
  • 7
    Reid PC, Urano Y, Kodama T, Hamakubo T. Alzheimer's Disease: cholesterol, membrane rafts, isoprenoids and statins. J Cell Mol Med. 2007; 11: 38392.
  • 8
    Pluta R. Role of ischemic blood-brain barrier on amyloid plaques development in Alzheimer's disease brain. Curr Neurovasc Res. 2007; 4: 1219.
  • 9
    Romanitan MO, Popescu BO, Winblad B, Bajenaru OA, Bogdanovic N. Occludin is overexpressed in Alzheimer's disease and vascular dementia. J Cell Mol Med. 2007; 11: 56979.
  • 10
    LaFerla FM, Green KN, Oddo S. Intracellular amyloid- beta in Alzheimer's disease. Nat Rev Neurosci. 2007; 8: 499509.
  • 11
    Arispe N, Diaz JC, Simakova O. Abeta ion channels. Prospects for treating Alzheimer's disease with Abeta channel blockers. Biochim Biophys Acta. 2007; 1768: 195265.
  • 12
    Nagy Z. The last neuronal division: a unifying hypothesis for the pathogenesis of Alzheimer's disease. J Cell Mol Med. 2005; 9: 53141.
  • 13
    Forero DA, Casadesus G, Perry G, Arboleda H. Synaptic dysfunction and oxidative stress in Alzheimer's disease: emerging mechanisms. J Cell Mol Med. 2006; 10: 796805.
  • 14
    Lasn H, Winblad B, Bogdanovic N. Neuroglia in the inferior olivary nucleus during normal aging and Alzheimer's disease. J Cell Mol Med. 2006; 10: 14556.
  • 15
    Cowburn RF, Popescu BO, Ankarcrona M, Dehvari N, Cedazo-Minguez A. Presenilin-mediated signal transduction. Physiol Behav. 2007; 92: 937.
  • 16
    Holzgrabe U, Kapková P, Alptüzün V, Scheiber J, Kugelmann E. Targeting acetylcholinesterase to treat neurodegeneration. Expert Opin Ther Targets. 2007; 11: 16179.
  • 17
    Blennow K. CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagn. 2005; 5: 66172.
  • 18
    Stewart AJ, Fox A, Morimoto BH, Gozes I. Looking for novel ways to treat the hallmarks of Alzheimer's disease. Expert Opin Investig Drugs. 2007; 16: 118396.
  • 19
    Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDSADRDA criteria. Lancet Neurol. 2007; 6: 73446.
  • 20
    Foster NL. A new framework for the diagnosis of Alzheimer's disease. Lancet Neurol. 2007; 6: 6679.
  • 21
    Cedazo-Minguez A. Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J Cell Mol Med. 2007; 11: 122536.
  • 22
    Wang JZ, Grundke-Iqbal I, Iqbal K. Kinases and phos-phatases and tau sites involved in Alzheimer neurofibril-lary degeneration. Eur J Neurosci. 2007; 25: 5968.